Two coronavirus vaccines, produced by both Pfizer and German company BioNTech were given Fast Track status by the FDA.
The vaccines, named BNT162b1 and BNT162b2, are some of the most advanced in the world. Early data from the earlier phases in testing is promising. Many participants that took the vaccine developed antibodies against the virus. The FDA grant allows Pfizer and BioNTech to work faster. Because of this, their vaccines could get to the market sooner.
Pfizer is planning to enroll up to 30,000 American volunteers to finish their vaccine testing.
If all goes well and as planned, 100 million doses are planned to be produced by the end of the year. 1.2 billion doses will be produced by the end of next year.